Reports Q4 revenue $46,000 vs. $69,000 last year. Matt Fisch, AEye (LIDR) CEO, said, “AEye just closed out a transformational year marked by ...

Reports Q4 revenue $1.02B, consensus $1.02B. “Akamai (AKAM) delivered a solid fourth quarter, demonstrating robust profitability and sustained ...

The company reported impressive earnings, bolstered by cloud adoption and AI advancements. Five9 achieved a non-GAAP EPS of $0.79, beating Wall Street forecasts of $0.70. Revenue for the quarter was ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

UnitedHealth Group's Q4 results showed mixed performance, with a beat on EPS but a miss on the Medical Loss Ratio. Read why I ...

Five9 provided full-year 2025 revenue guidance of $1.14 billion, representing an $11.5 million increase from the high-level outlook provided last quarter. Non-GAAP EPS is expected to reach a midpoint ...

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

Q4 2024 Management View CEO Jeff Lorenger noted that non-GAAP EPS for 2024 reached $3.06, a 15% year-over-year increase, marking the third consecutive year of double-digit growth. Workplace ...

Q4 2024 Management View CEO Jason Wells highlighted the company’s non-GAAP EPS of $0.40 for the quarter and $1.62 for the full year 2024, translating to 8% growth over 2023. He reaffirmed the 2025 non ...

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

2024 Diluted GAAP EPS of $3.65, compared to $3.22 in 2023. 2024 Adjusted Diluted Non-GAAP EPS of $3.40, compared to $3.27 in 2023. Affirms 4% to 6% long-term EPS growth rate. Increases quarterly ...